(+/-)-Lisuride | 860177-23-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: (+/-)-Lisuride
• 英文别名: 1,1-diethyl-3-(6-methyl-9,10-didehydro-ergolin-8-yl)-urea；S-(-)-Lisuride；1,1-diethyl-3-(7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinolin-9-yl)urea
• CAS: 860177-23-7
• 化学式: C₂₀H₂₆N₄O
• 分子量: 338.453
• InChiKey: BKRGVLQUQGGVSM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  51.4
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• METHODS AND PHARMACEUTICAL FORMULATIONS FOR TREATMENT OF SELECTIVE ESTROGEN-RECEPTOR MODULATOR-INDUCED ADVERSE DRUG REACTIONS
  申请人：Limoxifen B.V.

  公开号：EP3068433A1

  公开（公告）日：2016-09-21
• COMPOSITION AND USE FOR THE TREATMENT OF PARKINSON'S DISEASE AND RELATED DISORDERS
  申请人：Chase Therapeutics Corporation

  公开号：EP3856168A1

  公开（公告）日：2021-08-04
• Combination of a dopamine D2-receptor agonist and tiotropium or a derivative therof for treating obstructive airways and other inflammatory diseases
  申请人：Yeadon Michael

  公开号：US20070117788A1

  公开（公告）日：2007-05-24

  The present invention relates to a combination of therapeutic agents useful in the treatment of obstructive airways and other inflammatory diseases comprising (I) a dopamine D2-receptor agonist that is therapeutically effective in the treatment of said diseases when administered by inhalation; together with (II) an anti-cholinergic agent consisting of a member selected from the group consisting of tiotropium and derivatives thereof that is therapeutically effective in the treatment of said diseases when administered by inhalation; as well as to a method of treating said obstructive airways and other inflammatory diseases comprising administering to said mammal by inhalation a therapeutically effective amount of said combination of therapeutic agents; and a pharmaceutical composition comprising a pharmaceutically acceptable carrier together with said combination of therapeutic agents; and a package containing a pharmaceutical composition for insertion into a device capable of simultaneous or sequential delivery of said pharmaceutical composition in the form of an aerosol or dry powder dispersion to said mammal, where said device is a metered dose inhaler or a dry powder inhaler. It is preferred that said dopamine D2-receptor agonist component be bromocriptine mesylate, naxagolide hydrochloride, cabergoline, pergolide mesylate, quinpirole hydrochloride, or ropinirole hydrochloride; and that said anti-cholinergic agent component be tiotropium bromide.
• COMPOSITIONS AND METHODS TO REDUCE PATHOGENESIS
  申请人：The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College

  公开号：US20200078335A1

  公开（公告）日：2020-03-12

  This invention is directed to compositions, methods and kits for ameliorating or reducing pathogenesis of a disease by administering to a subject a serotonin receptor agonist.
• COMPOSITIONS AND METHODS FOR TREATING OCULAR PATHOLOGIES
  申请人：The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College

  公开号：US20200330405A1

  公开（公告）日：2020-10-22

  This invention features compositions, methods, and kits for treating conditions associated with pathological ocular neovascularization, reducing scarring in the eye, treating dry eye, treating macular degeneration, and treating keratitis by administering a serotonin receptor agonist.